BioMérieux Overview

  • Year Founded
  • 1963

Year Founded

  • Status
  • Public

  • Employees
  • 15,226

Employees

  • Stock Symbol
  • BIM

Stock Symbol

  • Investments
  • 61

  • Share Price
  • $102.54
  • (As of Friday Closing)

BioMérieux General Information

Description

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.

Contact Information

Formerly Known As
B-D Mérieux
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 376 Chemin de l'Orme
  • 100 allée Louis Pasteur
  • 69280 Marcy-l'Etoile
  • France
+33 04
Primary Industry
Diagnostic Equipment
Other Industries
Pharmaceuticals
Stock Exchange
PAR
Corporate Office
  • 376 Chemin de l'Orme
  • 100 allée Louis Pasteur
  • 69280 Marcy-l'Etoile
  • France
+33 04

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioMérieux Stock Performance

As of 13-Nov-2026, BioMérieux’s stock price is $102.54. Its current market cap is $12.1B with 118M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$102.54 $102.40 $74.96 - $136.01 $12.1B 118M 167K $4.58

BioMérieux Financials Summary

As of 30-Jun-2026, BioMérieux has a trailing 12-month revenue of $4.66B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 9,133,825 15,449,542 13,011,611 13,240,766
Revenue 4,655,118 4,590,759 4,306,645 3,976,194
EBITDA 915,252 956,436 970,643 769,464
Net Income 539,633 448,382 467,683 386,950
Total Assets 6,501,399 6,548,148 6,004,100 5,813,519
Total Debt 481,644 541,969 510,088 573,592
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioMérieux Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioMérieux‘s full profile, request access.

Request a free trial

BioMérieux Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing p
Diagnostic Equipment
Marcy-l'Etoile, France
15,226 As of 2025

Hercules, CA
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioMérieux Competitors (14)

One of BioMérieux’s 14 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bio-Rad Laboratories Corporation Hercules, CA
GSK Corporation London, United Kingdom
Hologic Private Equity-Backed Marlborough, MA
Sartorius Corporation Goettingen, Germany
Novartis Corporation Basel, Switzerland
You’re viewing 5 of 14 competitors. Get the full list »

BioMérieux Patents

BioMérieux Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3174570-A1 Analysis support including a chip and a chip Pending 25-Apr-2025
WO-2026224444-A1 Array substrate comprising a chip, and chip Pending 25-Apr-2025
WO-2026171756-A1 Dna/rna-dependent fluorescent compounds, and uses thereof Pending 13-Feb-2025
EP-4793322-A1 Fluorescent dna/rna-dependent compounds and uses thereof Pending 13-Feb-2025
WO-2026125835-A1 Capsule and method for compartmentalizing extraction particles in a container Pending 13-Dec-2024 B01J13/02
To view BioMérieux’s complete patent history, request access »

BioMérieux Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioMérieux Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioMérieux‘s full profile, request access.

Request a free trial

BioMérieux Investments & Acquisitions (61)

BioMérieux’s most recent deal was a Later Stage VC with Plair (Medical devices) for . The deal was made on 27-Mar-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Plair (Medical devices) 27-Mar-2026 Later Stage VC Monitoring Equipment
Accellix 22-Jan-2026 Merger/Acquisition Diagnostic Equipment
Allergen Alert 14-Oct-2025 Early Stage VC Information Services (B2C)
Suzhou Hybiome Biomedical Engineering 31-Jul-2025 Secondary Transaction - Private Diagnostic Equipment
Day Zero Diagnostics 13-Jun-2025 Merger/Acquisition Diagnostic Equipment
You’re viewing 5 of 61 investments and acquisitions. Get the full list »

BioMérieux ESG

Risk Overview

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Devices

Subindustry

Rank

Percentile

To view BioMérieux’s complete esg history, request access »

BioMérieux Exits (13)

BioMérieux’s most recent exit was on 17-Jan-2023 from InDevR. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
InDevR 17-Jan-2023 Completed
  • 2 buyers
Qvella 04-Dec-2017 Completed
  • 6 buyers
Knome (US) 21-Jan-2014 Completed
  • 3 buyers
Quanterix 15-Nov-2012 Completed
  • 5 buyers
Knome (US) 01-Aug-2011 Early Stage VC Completed
You’re viewing 5 of 13 exits. Get the full list »

BioMérieux Affiliates

Subsidiaries (15)

Name Industry Location Year Founded
Lumed Sherbrooke, Canada 2012
Neoprospecta Florianopolis, Brazil 2011
Suzhou Hybiome Biomedical Engineering Suzhou, China 2009
Accellix San Jose, CA 2007
Ceeram La Chapelle-sur-Erdre, France 2005
You’re viewing 5 of 15 affiliates. Get the full list.  »

BioMérieux FAQs

  • When was BioMérieux founded?

    BioMérieux was founded in 1963.

  • Where is BioMérieux headquartered?

    BioMérieux is headquartered in Marcy-l'Etoile, France.

  • What is the size of BioMérieux?

    BioMérieux has 15,226 total employees.

  • What industry is BioMérieux in?

    BioMérieux’s primary industry is Diagnostic Equipment.

  • Is BioMérieux a private or public company?

    BioMérieux is a Public company.

  • What is BioMérieux’s stock symbol?

    The ticker symbol for BioMérieux is BIM.

  • What is the current stock price of BioMérieux?

    As of 13-Nov-2026 the stock price of BioMérieux is $102.54.

  • What is the current market cap of BioMérieux?

    The current market capitalization of BioMérieux is $12.1B.

  • What is BioMérieux’s current revenue?

    The trailing twelve month revenue for BioMérieux is $4.66B.

  • Who are BioMérieux’s competitors?

    Bio-Rad Laboratories, GSK, Hologic, Sartorius, and Novartis are some of the 14 competitors of BioMérieux.

  • What is BioMérieux’s annual earnings per share (EPS)?

    BioMérieux’s EPS for 12 months was $4.58.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process